Medical device company BIOTRONIK Neuro has launched Embrace One Proactive Intelligence, a proprietary AI capability that aims to advance proactive care for patients implanted with the Prospera Spinal Cord Stimulation (SCS) System.

BIOTRONIK Neuro collects more than 200 data points per patient daily through automatic, objective remote monitoring, and the new AI capability analyzes this data to identify early signals that may indicate a patient could benefit from additional support or therapy optimization, according to the company.

The AI model does not make clinical decisions or adjust therapy, but rather, it provides additional insight to BIOTRONIK Neuro’s Embrace One Care Team. This group of clinical specialists actively monitor patients and provide timely, personalized care between office visits to help prioritize patient outreach and follow-up support. Because Embrace One Proactive Intelligence uses data already collected through the Prospera system, it requires no additional effort from patients or healthcare providers, BIOTRONIK said.

The AI model’s ability to identify patients who may benefit from proactive outreach was demonstrated with real-world data presented at the recent American Society of Pain and Neuroscience (ASPN) Annual Meeting. In a prospective pilot study, the model identified 188 behavioral-pattern instances across 175 patients for review by the Embrace One Care Team. Patients responded to proactive outreach in 80.9% of cases. Overall, nearly 4 out of 5 cases resulted in targeted support from the Embrace One Care Team, including remote reprogramming, therapy optimization, and additional patient education.

“This level of support gives me great peace of mind,” said David Dickerson, MD, of Endeavor Health, in Chicago, Illinois. “One of the challenges in managing SCS therapy is that patients don’t always recognize how subtle changes in their behavior may impact pain relief. Proactive Intelligence strengthens the Embrace One Care Team’s ability to identify patients who may benefit from outreach, creating more opportunities to address issues proactively and connect patients with the support they need.”

Historically, post-implant SCS management has relied on patients recognizing therapy issues and initiating follow-up care themselves. BIOTRONIK Neuro has established a new standard for proactive SCS management that combines continuous passive monitoring with personalized support from the Embrace One Care Team. 

Real-time visibility into therapy performance and device data is designed to enable BIOTRONIK Neuro’s team of clinical experts to identify potential issues and help address them before pain relief is compromised. Embrace One Proactive Intelligence aims to enhance these capabilities through AI modeling that helps prioritize patients for proactive outreach by the Embrace One Care Team.

“BIOTRONIK Neuro is uniquely positioned to bring AI-assisted support to spinal cord stimulation because of the rich, continuously expanding real-world dataset generated through our remote monitoring capabilities,” said Holger Krumel, group CEO of BIOTRONIK. “This innovation reflects our longstanding commitment to developing technologies that support patients beyond the clinic. By combining remote monitoring, personalized support, and AI-driven intelligence, we are advancing proactive care and helping SCS patients achieve stable, long-term relief.”

A proven, widely used treatment for chronic pain is spinal cord stimulation is, which delivers electrical impulses to the spinal cord to modulate nerve activity and reduce pain signals. Traditional SCS systems often require frequent in-office visits for reprogramming, resulting in therapy delays, patient travel burdens, and higher costs, BIOTRONIK said.

Emerging expert recommendations highlight the potential benefits of SCS systems with remote monitoring capabilities, which enable timely adjustments, minimize in-person visits, and may improve long-term outcomes by enhancing therapy management and patient convenience.